Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04698681 · ClinicalTrials.gov registry record
NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial
A clinical trial, sponsored by Calithera Biosciences.
- Terminated
- Registry status
- 20
- Enrollment target
NCT04698681 is a clinical trial that was terminated before completion, run by Calithera Biosciences. The registered enrollment target is 20 participants.
The verdict
NCT04698681 was terminated before completion, sponsored by Calithera Biosciences.
- TERMINATED
- Registry status
- 20 participants
- Enrollment target
Study Summary
This is a multicenter screening protocol designed to identify patients with NSCLC who have tumor mutations in the KEAP1 or NRF2/NFE2L2 genes in order to determine potential eligibility for a biomarker selected clinical trial (CX-839-014, otherwise known as the KEAPSAKE trial). Circulating tumor DNA (ctDNA) present in blood samples collected from eligible patients will be analyzed by next generation sequencing (NGS) for selected biomarkers. A commercial liquid biopsy NGS test will be provided to study participants free of charge.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-01-19 |
| Est. Completion | 2022-02-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04698681
The ClinicalTrials.gov registry entry for NCT04698681 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calithera Biosciences, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04698681 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04698681 about?
NCT04698681 is a clinical study titled "NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial". This is a multicenter screening protocol designed to identify patients with NSCLC who have tumor mutations in the KEAP1 or NRF2/NFE2L2 genes in order to determine potential eligibility for a biomarker selected clinical trial (CX-839-014, otherwise known as the KEAPSAKE trial). Circulating tumor DNA ...
What is the current status of trial NCT04698681?
This trial is currently terminated. The enrollment target is 20 participants. The study started on 2021-01-19. Estimated completion is 2022-02-09.
Who is sponsoring clinical trial NCT04698681?
This trial is sponsored by Calithera Biosciences, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.